SM
ACRS icon

Sabby Management’s Aclaris Therapeutics ACRS Stock Holding History

Sabby Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-15,812
Closed -$292K – 311
2016
Q2 		$292K Buy
+15,812
New +$313K 0.02% 232

Other funds holding ACRS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sabby Management's ACRS Position: Q3 2016 in Review

Sabby Management sold out of Aclaris Therapeutics (ACRS) in Q3 2016, closing a stake of 15,812 shares — an estimated $292K sold.

Sabby Management first reported a position in ACRS in Q2 2016 and held it in 1 quarter. The position peaked at $292K in Q2 2016. 58 funds tracked by Wall St. Rank hold ACRS as of Q3 2016.

  • Sabby Management reported no remaining Aclaris Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Sabby Management sold 15,812 Aclaris Therapeutics shares in Q3 2016, an estimated $292K.
  • Sabby Management first reported a position in Aclaris Therapeutics in Q2 2016 and held it in 1 quarter.
  • Sabby Management's Aclaris Therapeutics position peaked at $292K in Q2 2016.
  • 58 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2016.

Based on Sabby Management's 13F filing for Q3 2016, filed 14 Nov 2016.